Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTA R FERNANDEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1780666750
CMS profile
528148
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$268.75

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $268.75 17

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTA R FERNANDEZ

NPI 1780666750 · CMS profile ID 528148

Allopathic & Osteopathic Physicians / General Practice

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780666750?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTA R FERNANDEZ, NPI 1780666750, CMS profile ID 528148. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780666750?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARTA R FERNANDEZ, NPI 1780666750, CMS profile ID 528148. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780666750?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARTA R FERNANDEZ, NPI 1780666750, CMS profile ID 528148, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780666750?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $268.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $11.5711/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700048645 CMS
AbbVie, Inc. $21.8910/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648030553 CMS
SANOFI-AVENTIS U.S. LLC $16.2410/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694188483 CMS
Janssen Pharmaceuticals, Inc $16.6610/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658575459 CMS
Amarin Pharma Inc. $16.4110/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699232195 CMS
GlaxoSmithKline, LLC. $17.0010/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671442899 CMS
Lilly USA, LLC $13.6909/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657990419 CMS
AbbVie, Inc. $16.4809/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648030551 CMS
AbbVie, Inc. $17.3508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648030549 CMS
Janssen Pharmaceuticals, Inc $14.9208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658575239 CMS
GlaxoSmithKline, LLC. $19.2508/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670917669 CMS
AstraZeneca Pharmaceuticals LP $14.3707/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685142183 CMS
Janssen Pharmaceuticals, Inc $15.0806/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658575021 CMS
PFIZER INC. $18.6805/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672688224 CMS
Hologic, LLC $12.9104/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 649999133 CMS
AbbVie, Inc. $13.8404/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648030555 CMS
Janssen Pharmaceuticals, Inc $12.4104/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658574789 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $268.75 17
PY2020 $646.46 40
PY2021 $668.82 29
PY2022 $324.00 6
PY2023 $18.96 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,841,652.05 193
PY2024 Principal investigator $1,804,097.28 110
PY2023 Principal investigator $359,279.61 15
PY2022 Principal investigator $244,054.37 49
PY2021 Principal investigator $232,528.97 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $8,536.65 12/21/2022 Non-covered Recipient Entity
SYSTEMS & STRUCTURE REHAB CENTER INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049043
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,000.00 12/20/2022 Non-covered Recipient Entity
NEW MED RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 933762007
Principal investigator 1 Incyte Corporation $28.98 12/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238359
Principal investigator 1 Incyte Corporation $39.94 12/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238361
Principal investigator 1 Incyte Corporation $199.32 12/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238363
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.57 12/07/2022 Non-covered Recipient Entity
SYSTEMS & STRUCTURE REHAB CENTER INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049033
Principal investigator 1 GlaxoSmithKline, LLC. $7,771.74 12/07/2022 Non-covered Recipient Entity
SYSTEMS & STRUCTURE REHAB CENTER INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049061
Principal investigator 1 GlaxoSmithKline, LLC. $9,216.75 11/18/2022 Non-covered Recipient Entity
SYSTEMS & STRUCTURE REHAB CENTER INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049023
Principal investigator 1 Incyte Corporation $25.02 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238321
Principal investigator 1 Incyte Corporation $44.64 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238323
Principal investigator 1 Incyte Corporation $20.26 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238325
Principal investigator 1 Incyte Corporation $0.90 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238327
Principal investigator 1 Incyte Corporation $20.42 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238329
Principal investigator 1 Incyte Corporation $42.88 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238331
Principal investigator 1 Incyte Corporation $50.04 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238333
Principal investigator 1 Incyte Corporation $1.42 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238335
Principal investigator 1 Incyte Corporation $5.68 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238337
Principal investigator 1 Incyte Corporation $4.65 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238339
Principal investigator 1 Incyte Corporation $0.32 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238341
Principal investigator 1 Incyte Corporation $2.08 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238343
Principal investigator 1 Incyte Corporation $40.76 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238345
Principal investigator 1 Incyte Corporation $35.08 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238347
Principal investigator 1 Incyte Corporation $74.13 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238349
Principal investigator 1 Incyte Corporation $10.20 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238351
Principal investigator 1 Incyte Corporation $4.00 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238353
Principal investigator 1 Incyte Corporation $19.38 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238355
Principal investigator 1 Incyte Corporation $42.00 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238357
Principal investigator 1 Incyte Corporation $25.02 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238365
Principal investigator 1 Incyte Corporation $20.42 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238367
Principal investigator 1 Incyte Corporation $25.02 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238369
Principal investigator 1 Incyte Corporation $25.02 11/08/2022 Non-covered Recipient Entity
BLESSED HEALTH CARE
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 905238371
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,052.00 10/19/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH, LLC
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914601501
Principal investigator 1 GlaxoSmithKline, LLC. $2,434.04 10/19/2022 Non-covered Recipient Entity
SYSTEMS & STRUCTURE REHAB CENTER INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049053
Principal investigator 1 Evofem Biosciences, Inc. $140.70 09/28/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900662175
Principal investigator 1 Evofem Biosciences, Inc. $1,482.84 09/09/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900662155
Principal investigator 1 Evofem Biosciences, Inc. $5,931.36 08/02/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661637
Principal investigator 1 Evofem Biosciences, Inc. $1,000.00 08/02/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661657
Principal investigator 1 Evofem Biosciences, Inc. $15,851.25 07/21/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660909
Principal investigator 1 Evofem Biosciences, Inc. $47,905.46 07/08/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660907
Principal investigator 1 Evofem Biosciences, Inc. $8,785.00 04/21/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661349
Principal investigator 1 Evofem Biosciences, Inc. $1,482.84 03/31/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660507
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,979.80 03/18/2022 Non-covered Recipient Entity
EPOCRATES MEDICAL AND RESEARCH CENTER MD, PA
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914595489
Principal investigator 1 Evofem Biosciences, Inc. $3,765.00 03/17/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660505
Principal investigator 1 Evofem Biosciences, Inc. $10,258.72 03/10/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660503
Principal investigator 1 Evofem Biosciences, Inc. $18,226.16 02/17/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661947
Principal investigator 1 Evofem Biosciences, Inc. $20,155.56 02/10/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661107
Principal investigator 1 Evofem Biosciences, Inc. $1,525.14 02/03/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900661105
Principal investigator 1 Evofem Biosciences, Inc. $16,319.96 01/20/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660347
Principal investigator 1 Evofem Biosciences, Inc. $4,425.25 01/07/2022 Non-covered Recipient Entity
US ASSOCIATES IN RESEARCH LLC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) No dispute reported 06/30/2026 900660345